Skip to main content

Table 1 Predictive factors for time to progression

From: Different role of circulating myeloid-derived suppressor cells in patients with multiple myeloma undergoing autologous stem cell transplantation

Univariate analysis RR (95% CI) P
 Age at diagnosis (years), continuous 1.00 (0.96–1.04) 0.855
 Sex (F vs. M) 0.92 (0.50–1.71) 0.802
 Durie-Salmon stage at diagnosis (III vs. II) 1.29 (0.54–3.08) 0.567
 ISS stage at diagnosis (III vs. I-II) 0.64 (0.29–1.39) 0.257
 Cytogenetics (high risk vs. standard) 1.81 (0.80–4.08) 0.155
 Immunoglobulin type (others vs. light chain only) 2.27 (1.04–4.93) 0.039
 Myeloma bone disease on plain radiographs (no vs. yes) 1.69 (0.89–3.919) 0.107
 Cr at diagnosis (mg/dL), (≥2 vs. < 2) 0.61 (0.29–1.28) 0.189
 Hb at diagnosis (g/dL), (≥8.5 vs. < 8.5) 0.58 (0.31–1.08) 0.084
 Ca at diagnosis (mg/dL), (≥10 vs. < 10) 1.01 (0.49–2.07) 0.985
 β2-microglobulin at diagnosis (mg/dL), (≥5.5 vs. < 5.5) 0.60 (0.28–1.31) 0.199
 Albumin at diagnosis (mg/dL), (≥3.5 vs. < 3.5) 0.58 (0.31–1.08) 0.083
 LDH at diagnosis (U/L), (≥450 vs. < 450) 1.20 (0.60–2.43) 0.607
Multivariate analysis RR (95% CI) P
 Immunoglobulin type (others vs. light chain only) 2.01 (0.77–5.24) 0.153
 Hb at diagnosis (g/dL), (≥8.5 vs. < 8.5) 0.79 (0.40–1.58) 0.507
 Albumin at diagnosis (mg/dL), (≥3.5 vs. < 3.5) 0.60 (0.30–1.020) 0.148
 Pre-ASCT M-MDSC frequency (Low vs. high) 0.49 (0.24–0.99) 0.045
  1. Ca Calcium, Cr Creatinine, CI Confidence interval, F Female, Hb Hemoglobin, LCD Light chain disease, LDH Lactate dehydrogenase, M Male, TTP Time to progression